UK Markets open in 3 hrs 22 mins

Sinopharm Group Co. Ltd. (X2S.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
2.0110-0.0290 (-1.42%)
At close: 01:07PM CET
Full screen
Previous close2.0400
Open2.0500
Bid0.0000 x 400000
Ask0.0000 x 400000
Day's range2.0110 - 2.0500
52-week range1.8500 - 2.9590
Volume1,770
Avg. volume8,298
Market cap6.189B
Beta (5Y monthly)0.80
PE ratio (TTM)6.36
EPS (TTM)0.3160
Earnings dateN/A
Forward dividend & yield0.09 (4.11%)
Ex-dividend date15 Jun 2021
1y target estN/A
  • Bloomberg

    China Vaccine Diplomacy Wavers as Nations Seek Western Shots

    (Bloomberg) -- In the early days of the Covid-19 vaccine rollout, Chinese shots saved countless lives. They kick-started inoculation programs across Asia, Latin America and the Middle East, while richer countries hoarded scarce mRNA shots from Pfizer Inc. and Moderna Inc.Most Read from BloombergChristmas at Risk as Supply Chain ‘Disaster’ Only Gets WorseReshaped by Crisis, an ‘Anti-Biennial’ Reimagines ChicagoThis Is What Europe’s Green Future Looks LikeWhy the Gaza Strip May Be the City of the

  • Yahoo Finance

    Delta variant sparks concerns, future mutations remain a threat

    The Delta variant is an increasing source of concern for health experts as vaccinations wane and the holiday weekend approaches in the U.S. Those at the highest risk are unvaccinated individuals and people living in pockets of states with low vaccination rates.

  • Reuters

    Exclusive: Sinopharm to inject $4.6 billion vaccine assets into unit Tiantan Biological - sources

    Chinese state-owned Sinopharm plans to inject 30 billion yuan ($4.6 billion) in assets into unit Beijing Tiantan Biological Products Corp Ltd to quickly get its fast-growing vaccine business on the public market, two people told Reuters. Sinopharm aims to begin the injection of six vaccine-focused biological products developers including makers of two COVID-19 vaccines into Shanghai-listed Tiantan in the coming weeks, said the people plus two other people with knowledge of the matter. The plan comes as China races to develop more homegrown COVID-19 vaccines to challenge Western rivals.